Statins and hepatotoxicity: Focus on patients with fatty liver

被引:202
作者
Chalasani, N [1 ]
机构
[1] Indiana Univ, Sch Med, Indianapolis, IN 46202 USA
关键词
D O I
10.1002/hep.20671
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
[No abstract available]
引用
收藏
页码:690 / 695
页数:6
相关论文
共 49 条
  • [41] Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S)
    Strandberg, TE
    Pyörälä, K
    Cook, TJ
    Wilhelmsen, L
    Faergeman, O
    Thorgeirsson, G
    Pedersen, TR
    Kjekshus, J
    [J]. LANCET, 2004, 364 (9436) : 771 - 777
  • [42] *THOMPS HEALTHC, 2005, PHYS DESK REF 2005
  • [43] Statin-associated myopathy
    Thompson, PD
    Clarkson, P
    Karas, RH
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (13): : 1681 - 1690
  • [44] The liver and lovastatin
    Tolman, KG
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2002, 89 (12) : 1374 - 1380
  • [45] Tolman KG, 2000, AM J CARDIOL, V85, p15E
  • [46] VESSEY D, 2003, HEPATOLOGY TXB LIVER, P185
  • [47] Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes
    Vuppalanchi, RAJ
    Teal, E
    Chalasani, N
    [J]. AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2005, 329 (02) : 62 - 65
  • [48] Hepatic cytochrome p450 2E1 is increased in patients with nonalcoholic steatohepatitis
    Weltman, MD
    Farrell, GC
    Hall, P
    Ingelman-Sundberg, M
    Liddle, C
    [J]. HEPATOLOGY, 1998, 27 (01) : 128 - 133
  • [49] *WWW DRUGTOPICS CO, PHARM FACTS FIG